噻托溴铵奥达特罗能倍乐国内上市了吗

COPD (chronic obstructive pulmonary disease) is a very common chronic disease in my country, and its treatment faces many challenges. COPD is a type of chronic bronchitis and emphysema characterized by airflow obstruction. Common symptoms include chronic cough, shortness of breath, chest tightness, etc., which often occur in the cold season. Although a number of drugs have been developed to treat COPD in the past decade or so, there are still huge unmet medical needs in this disease. The launch of the drug has brought new treatment options to patients with COPD.

So has tiotropium bromide olodaterol Respimat been launched in China? It is understood that tiotropium bromide, olodaterol and Respimat are already on the market in the country. Patients can buy it at domestic pharmacies with a prescription.

Bronchodilators are the main therapeutic drugs for improving the symptoms of COPD and have a certain effect on reducing the risk of acute exacerbation. They are the first-line basic drugs for the treatment of stable COPD. Tiotropium bromide is a classic LAMA. Compared with other LAMAs, tiotropium bromide has a stronger affinity for the M3 receptor, a slower dissociation rate, and longer clinical application experience. As the core drug in the treatment of COPD, tiotropium bromide is the world's first inhaled long-acting anticholinergic drug and a classic drug recommended by domestic and foreign guidelines for the treatment of COPD. This product was launched in my country in 2006 and has 12 years of clinical application experience. "Clinical studies have proven that putting tiotropium bromide and olodaterol in the same inhalation device can not only provide efficacy beyond single drug treatment for COPD, but also be as safe as single drug treatment.

Dual-branched Sihehua Rebeimab is based on tiotropium bromide and adds a new long-acting β2 receptor agonist - olodaterol. The two drugs can achieve complementary mechanisms and synergistic effects. The latest GOLD (Global Initiative for the Diagnosis, Treatment and Prevention of COPD) guidelines also clearly point out that bronchodilator combination therapy is more effective than bronchodilator monotherapy in preventing acute exacerbations of COPD. Patients can use it under the guidance of experienced doctors and pay attention to safe medication use.

Recommended hot article: The efficacy of Afinitor on kidney cancer